Building on previous reports indicating that human MSCs upregulate programmed death-ligand 1 (PD-L1) under inflammatory conditions,21 we hypothesise that MSC therapy ameliorates SSc-ILD by reprogramming the PD-1/PD-L1 axis in CD4+ T cell subsets. Here, CD4 is linked to systemic sclerosis.